Cap Analogs

Uracil-m7GpppAmpG ammonium solution (100 mM) is a cap analog that can be used for mRNA synthesis.

m7GpppUpG, an oligonucleotide, is an M⁷GpppNpG trinucleotide cap analogue. m7GpppUpG can be used as a chemical tool enabling manufacturing of RNA featuring either cap 0 or cap 1 structures.

m7GpppUmpG, an oligonucleotide, is an M⁷GpppNpG trinucleotide cap analogue. m7GpppUmpG can be used as a chemical tool enabling manufacturing of RNA featuring either cap 0 or cap 1 structures.

m7Gpppm6AmpG is a trinucleotide mRNA 5’ cap analogs. m7Gpppm6AmpG can be used for RNA synthesis in vitro.

m7GpppCpG, an oligonucleotide, is an M⁷GpppNpG trinucleotide cap analogue. m7GpppCpG can be used as a chemical tool enabling manufacturing of RNA featuring either cap 0 or cap 1 structures.

m7GpppCmpG, an oligonucleotide, is an M⁷GpppNpG trinucleotide cap analogue. m7GpppCmpG can be used as a chemical tool enabling manufacturing of RNA featuring either cap 0 or cap 1 structures.

3’OMe-m7GpppAmpG (m7(3'OMeG)(5')ppp(5')(2'OMeA)pG) is a trinucleotide Cap1 analog with the structure m7 (3'OMeG)(5') ppp (5')(2'OMeA) pG, and also functions as a cis-acting ligase ribozyme inhibitor. 3’OMe-m7GpppAmpG effectively reduces free 5'-triphosphate groups on RNA transcripts, thereby enabling efficient co-transcriptional capping of in vitro transcribed mRNA. 3’OMe-m7GpppAmpG is not only widely used in the preparation of modified mRNA including trivalent influenza vaccine candidates, but also applicable to studies related to SARS-CoV-2 infection and other relevant research.

7-Methyl-diguanosine triphosphate (m7Gp3G) is an mRNA cap structure analog that inhibits in vitro protein synthesis by binding to the translation initiation complex. 7-Methyl-diguanosine triphosphate binds to eIF4E, promotes cap-dependent translation initiation, stabilizes mRNA, and acts as a translation enhancer. 7-Methyl-diguanosine triphosphate can be used to prepare synthetic capped RNA transcripts for studies related to mRNA translation, splicing, turnover, and intracellular transport.

m7(3'AcmG)(5')ppp(5')(2'OMeA)pG ammonium, a cap analogue derived from patent WO2023159930A1, can be used for the synthesis of mRNA.

m7(3'Ma-Cy7)Gppp(2'OMe)ApG ammonium is a Cy7-labled cap analogue that can be used for mRNA synthesis. The efficiency of mRNA delivery can be determined by the detection of Cy7 by flow cytometry, which can be used to track mRNA in cells and in living animals and to screen delivery lipid ratios.

m7GpppGpG is an unmodified trinucleotide cap analog with enhancer activity. When incorporated into mRNA, it effectively enhances translational efficiency, stability, and protein expression levels of the mRNA. m7GpppGpG can serve as a standard cap analog for in vitro mRNA synthesis to support antigen generation and presentation by dendritic cells, although its expression efficiency in dendritic cells is 20-fold lower than that of the m7GpppApG cap.

m7GpppAmpG (m7G(5')ppp(5')(2'OMeA)pG) is a trinucleotide 5′ cap analog. m7GpppAmpG binds to eIF4E with a K_D value of 45.6 nM. m7GpppAmpG caps RNA with an efficiency of 90% and enhances mRNA stability and translation efficiency. m7GpppAmpG is used in mRNA therapeutic research.

m7GpppApG is a trinucleotide mRNA 5' cap analog that can be used for RNA synthesis in vitro.